SRTS · XBRL financial data

Sensus Healthcare financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SRTS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	9,577	27,042	44,532	24,405	41,807	27,482
Revenue from contracts with customers	—	—	—	24,405	41,807	27,482
Cost of goods and services sold	4,328	10,054	14,904	10,345	17,376	15,615
Gross profit	5,249	16,988	29,628	14,060	24,431	11,867
Research and development	4,157	3,436	3,460	3,678	4,216	7,778
Selling, general and administrative	—	—	—	5,156	7,147	7,873
General and administrative	3,989	4,594	5,008	5,156	—	—
Total operating expenses	13,483	12,868	14,797	14,442	16,341	22,174
Operating income (loss)	(8,234)	4,120	14,831	(382)	8,090	(10,307)
Interest expense	14	2	2	(992)	(932)	—
Other income (expense)	—	—	13,159	1,034	932	683
Income tax expense (benefit)	—	—	3,746	167	2,375	(1,905)
Net income (loss)	(6,836)	4,119	24,244	485	6,647	(7,719)
Earnings per share, basic USD per share	(0.42)	0.25	1.47	0.03	0.41	(0.47)
Earnings per share, diluted USD per share	(0.42)	0.25	1.46	0.03	0.41	(0.47)
Weighted average shares, basic thousands of shares	16,434	16,476	16,481	16,259	16,312	16,327
Weighted average shares, diluted thousands of shares	16,434	16,503	16,618	16,266	16,360	16,327

Fiscal years (SRTS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	14,907	14,519	25,520	23,148	22,056	22,083
Accounts receivable	3,776	12,130	17,299	10,645	19,731	6,041
Inventory	4,427	1,759	3,501	11,861	10,097	14,563
Prepaid and other current assets	2,061	2,837	6,921	—	—	—
Total current assets	25,171	31,245	53,241	49,528	56,738	45,892
Property and equipment, net	1,356	605	243	464	1,997	1,976
Right-of-use asset	1,076	169	996	774	581	452
Total assets	28,010	32,240	56,735	53,710	62,165	53,039
Total current liabilities	4,856	5,963	7,697	4,212	5,885	4,722
Lease liability, non-current	812	—	830	596	398	209
Total liabilities	6,514	6,225	8,666	4,868	6,338	4,941
Retained earnings (accumulated deficit)	(22,061)	(17,942)	6,302	6,787	13,434	5,715
Total stockholders' equity	21,496	26,015	48,069	48,842	55,827	48,098
Total liabilities and equity	28,010	32,240	56,735	53,710	62,165	53,039
Common shares outstanding (cover page) thousands of shares	16,486	16,657	16,397	16,394	16,495	16,462

Fiscal years (SRTS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(6,836)	4,119	24,244	485	6,647	(7,719)
Stock-based compensation	386	415	187	328	323	295
Depreciation and amortization	722	613	315	—	—	—
Net cash from operating activities	(434)	(286)	(1,412)	(2,145)	(831)	528
Purchases of property and equipment	359	128	159	229	276	196
Net cash from investing activities	7,031	129	14,841	(187)	(276)	(196)
Share repurchases	—	—	2,999	27	—	300
Net cash from financing activities	210	(231)	(2,428)	(40)	15	(305)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Sensus Healthcare	15,186	2,290	(3,133)*	16.5M	4.8 quarters	Q2 FY26 10-QJun 30, 2026
Spectral AI	14,000	3,524	(4,097)*	32.2M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Pro Dex	11,759	20,560	6,490	3.2M	—	Q1 FY27 10-QSep 30, 2026
enVVeno Medical	2,585	not reported	(3,178)*	694,826	5.6 quarters	Q3 FY26 10-QSep 30, 2026
TELA Bio	30,424	19,291	(9,381)*	44.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Orchestra BioMed Holdings	20,472	88	(19,332)*	60.1M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Apyx Medical	27,617	13,884	(3,490)*	42.1M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
Myomo	11,219	11,705	(1,944)*	39.6M	6.9 quarters	Q2 FY26 10-QJun 30, 2026
Edap TMS	21,542	13,203	(3,691)*	37.5M	6.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.